Navigation Links
Lifelong Antiretroviral Treatment for HIV-Infected Pregnant Women Prevents Infection in Children, Saves Mothers' Lives, Study Finds
Date:3/12/2013

BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Providing life-long antiretroviral treatment to HIV-infected pregnant women not only prevents HIV infections in infants, but also improves the 10-year survival rate in mothers, saving more than 250,000 maternal life years and reducing the likelihood that children born to these mothers will become orphans, a study published today in the journal PLOS ONE found.

Transmission of HIV during pregnancy, labor, delivery or breastfeeding is the main mode of HIV infection in children. An estimated 390,000 children worldwide acquired HIV from their mothers in 2010, with more than 90 percent of these new infections occurring in sub-Saharan Africa. Malawi, a low-income country of 15 million people, is one of the countries with the highest number of HIV-infected pregnant women.

The study from Abt Associates' Dr. Carlos Avila and colleagues examined how the Ministry of Health in Malawi is implementing a new program termed Option B+, in which all pregnant women who test HIV positive are placed on antiretroviral therapy (ART) for life, regardless of their CD4 count or clinical stage.

They looked at whether the program represents a cost-effective policy option for treating HIV-infected pregnant women and for preventing mother-to-child transmission, as compared with World Health Organization guidelines (Option A and B) to prevent mother-to-child transmission of HIV. Those guidelines recommend antiretroviral therapy for women with CD4 counts at or lower than 350 cells per microliter, which presents a major restriction in areas where lab resources are scarce. Under WHO Option A, the mother receives antiretrovirals at three different stages of pregnancy and then for a week after childbirth. Under WHO Option B, the mother takes a triple antiretroviral regimen at 14 weeks, and continues taking this treatment until the child is born. Antiretrovirals are suspended after delivery, or one week after all infant exposure to breast milk has ended. The infants receive antiretroviral prophylaxis.

Researchers used data from Malawi to simulate the progression of HIV among a group of HIV-infected pregnant women who received preventive and antiretroviral therapy, and estimated the number of pediatric infections averted and maternal life years gained over a 10-year period. They found that providing lifelong antiretroviral treatment to all mothers would improve 10-year survival in mothers more than four-fold, saving more than 250,000 maternal life years, as compared to mothers receiving other treatment options, which saved 153,000 and 172,000 life years respectively. In addition, providing ARTs for all HIV-infected pregnant women could save $455 U.S. per life year gained.

"Although providing these drugs may cost more in the short term, it will save many lives, prevent future infant infections and reduce the chances that a child will become an orphan in the long term," said Avila, a senior health economist at Abt. "This study takes into account the realities of providing antiretrovirals in rural Africa, where lab facilities are scarce and requirements to start treatment based on CD4 counts are a major impediment to mothers getting the treatment they need."

The researchers also note that simplifying drug regimen options may improve adherence to therapy and can help overcome some of the individual, organizational and societal barriers to achieving high coverage levels of prophylaxis and treatment.

For the full paper, please visit: http://dx.plos.org/10.1371/journal.pone.0057778

About Abt Associates
Abt Associates is a mission-driven, global leader in research and program implementation in the fields of health, social and environmental policy, and international development. Known for its rigorous approach to solving complex challenges, Abt Associates is regularly ranked as one of the top 20 global research firms and one of the top 40 international development innovators. The company has multiple offices in the U.S. and program offices in nearly 40 countries. www.abtassociates.com


'/>"/>
SOURCE Abt Associates
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
3. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
4. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
5. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
6. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
7. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
8. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
9. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
10. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
11. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... Feb. 11, 2016 Potrero Medical, Inc., the developer ... announce the appointment of George M. Rapier, III , ... Antonio, TX , WellMed is one of the nation,s ... and HMO members in Texas and ... out of his own internal medicine practice, he has been ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... Atlanta, GA (PRWEB) , ... February 12, 2016 ... ... and relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards ... categories will be announced at the ISE® Southeast Executive Forum and Awards Gala ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Every winter, someone ... This winter the West Penn Burn Center, part of the Allegheny Health ... to bring you the “Space Heaters Need Space” campaign. , “Space ...
(Date:2/12/2016)... ... ... The Jones Agency, a family owned insurance company with offices serving Arlington, Dallas, ... with the Tarrant Area Food Bank in the hopes of alleviating hunger for nearby ... Tarrant County Food Bank offers hope and security to the one in six Texas ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a full ... of the latest charity campaign in their community enrichment program. Art Expression utilizes ... worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression ...
Breaking Medicine News(10 mins):